Subsequently, more extensive studies confirmed that even in heavily pretreated BRCA1/2 mutation carriers with ovarian cancer, olaparib delivered a median duration of response of 8 months (Domchek et al., 2016; Matulonis et al., 2016), while a similar benefit was seen in patients with BC with a BRCA1/2 mutation only in the sensitive first-line setting (Robson et al., 2017). Here, BRCA1 is linked to breast cancer.